ESMO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Prostate
OR
Chapter selection available inside video player. Click here for outline.
00:10
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
10:22
LBA66 UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA-617 and Docetaxel (D) versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
14:53
LBA1 A randomised multicentre open-label phase III trial comparing enzalutamide vs. a combination of radium-223 (223Ra) and enzalutamide in asymptomatic or mildly symptomatic patients with castration-resistant prostate cancer and bone metastases. First results of EORTC-1333/PEACE III
Chair
Dr. Christian Kollmannsberger
Panelists
Dr. Maria Jiang
Dr. Sebastian Hotte
